Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.14M Sell
17,793
-156
-0.9% -$18K 0.2% 59
2025
Q4
$1.89M Sell
17,949
-776
-4% -$72.8K 0.18% 64
2025
Q3
$1.57M Sell
18,725
-2,040
-10% -$168K 0.15% 76
2025
Q2
$1.64M Sell
20,765
-784
-4% -$62.3K 0.18% 66
2025
Q1
$1.93M Sell
21,549
-919
-4% -$85.8K 0.23% 55
2024
Q4
$2.24M Sell
22,468
-982
-4% -$101K 0.27% 49
2024
Q3
$2.66M Buy
23,450
+114
+0.5% +$13.5K 0.33% 39
2024
Q2
$3.08M Hold
23,336
0.44% 32
2024
Q1
$3.08M Sell
23,336
-152
-0.6% -$18.7K 0.44% 32
2023
Q4
$2.56M Buy
23,488
+1,696
+8% +$176K 0.4% 35
2023
Q3
$2.24M Buy
21,792
+18,709
+607% +$2.02M 0.38% 40
2023
Q2
$356K Sell
3,083
-1,263
-29% -$143K 0.09% 55
2023
Q1
$462K Buy
4,346
+42
+1% +$4.54K 0.12% 44
2022
Q4
$477K Buy
4,304
+156
+4% +$15.9K 0.12% 41
2022
Q3
$357K Buy
+4,148
New +$370K 0.1% 48
2020
Q4
Sell
-4,388
Closed -$347K 89
2020
Q3
$347K Buy
4,388
+485
+12% +$38K 0.22% 50
2020
Q2
$288K Sell
3,903
-47
-1% -$3.54K 0.26% 43
2020
Q1
$290K Buy
3,950
+434
+12% +$34.1K 0.26% 37
2019
Q4
$305K Buy
+3,516
New +$289K 0.16% 38

Other funds holding MRK

Compass Ion Advisors's MRK Position: Q1 2026 in Review

Compass Ion Advisors reduced its Merck (MRK) stake by 0.87% in Q1 2026, selling an estimated $18K and leaving 17,793 shares worth $2.14M. The position accounts for 0.2% of the portfolio, ranked #59.

Compass Ion Advisors first reported a position in MRK in Q4 2019 and has held it in 19 quarters since. The position peaked at $3.08M in Q2 2024. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Compass Ion Advisors held 17,793 shares of Merck worth $2.14M as of Q1 2026.
  • Compass Ion Advisors sold 156 Merck shares in Q1 2026, an estimated $18K.
  • Merck made up 0.2% of Compass Ion Advisors's portfolio in Q1 2026, its #59 holding.
  • Compass Ion Advisors first reported a position in Merck in Q4 2019 and has held it in 19 quarters since.
  • Compass Ion Advisors's Merck position peaked at $3.08M in Q2 2024.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Compass Ion Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.